Apollo Makes Strategic Investment In European Pharma VC Sofinnova Partners

Apollo Partners (NYSE: APO) and Sofinnova Partners announced a long-term strategic and financial partnership. As per the announcement, Apollo will acquire a minority stake in the pioneering life sciences venture capital firm. Furthermore, it will also provide up to $1.05 billion in capital commitments.

Moreover, this agreement is of special strategic importance to Apollo. This is because Sofinnova adds to Apollo’s existing ecosystem of investments focused on deep tech, digital assets and specialized, higher growth categories where the firm does not have a historic footprint.

Thus with this investment, Apollo will be able to maintain its disciplined investment approach. Along with this, it will also be able to leverage this new sector expertise across its equity, hybrid an...

Login In


Register now for free access

Notify of
Inline Feedbacks
View all comments